The distinction is crucial because DNA alone provides only a partial view of cancer. Genomic sequencing can reveal mutations, chromosome alterations and changes in gene regulation, but a mutation does not automatically tell researchers whether a pathway is active, inactive or therapeutically important. Proteomics adds another layer by measuring proteins, the molecular machines that execute most cellular functions. Metabolomics goes further downstream, examining small molecules such as amino acids, lipids, nucleotides and energy-related compounds produced or consumed by cells. Together, these measurements can expose the chain of events linking an alteration in the genome to a functional dependency inside a malignant cell. In practical terms, the approach asks not only what has changed in an AML cell, but what that cell is doing—and what it may be unable to survive without.

The researchers’ integrated strategy is designed to identify molecular subtypes that may be invisible when each data type is analyzed separately. A leukemia sample might carry a mutation that appears modest on its own, while simultaneously displaying a distinctive protein abundance pattern and an unusual metabolic state. When these signals converge, they can reveal a coherent biological program. One group of leukemias may be organized around altered signaling, another around disrupted protein production, and another around exceptional reliance on particular nutrient or energy pathways. Such classifications are potentially more informative than broad diagnostic categories because they are linked to mechanisms that can be tested in the laboratory and, ultimately, targeted with drugs.

Metabolism is especially important in AML because malignant cells must continuously generate energy and raw materials while coping with the demands of rapid growth. Leukemia cells can rewire how they process glucose, amino acids, fatty acids and nucleotides, sometimes using pathways that normal blood-forming cells use only under stress. This flexibility can help cancer cells survive in the bone marrow, where oxygen and nutrients are unevenly distributed. It can also create vulnerabilities. A cell that becomes heavily dependent on one metabolic route may be damaged when that route is blocked, even if healthy cells can switch to alternatives. By placing metabolite measurements alongside protein and genomic data, the study seeks to distinguish general features of aggressive leukemia from specific biochemical dependencies that could become therapy targets.

The same logic applies to proteins involved in signaling and gene regulation. Mutated DNA may activate a kinase cascade, stabilize a transcription factor or interfere with the machinery that controls cell maturation. Yet the therapeutic value of such a change depends on whether the resulting protein network remains active in the patient’s leukemia. Proteogenomic analysis can help answer that question by measuring both protein abundance and, where possible, chemical modifications such as phosphorylation. Phosphorylation acts as a molecular switch in many signaling pathways, turning proteins on or off or changing where they operate in the cell. Detecting abnormal phosphorylation patterns can therefore reveal active signaling circuits that sequencing alone might miss, as well as identify nodes that could be blocked pharmacologically.

A major promise of the work is the identification of therapy targets associated with particular AML subtypes. Target discovery in cancer is often difficult because a molecule may be altered without being essential, or because blocking it may harm normal tissues more than tumor cells. Integrated profiling can prioritize candidates by showing that a protein or pathway is not merely present, but connected to a broader network of genomic and metabolic abnormalities. Researchers can then test whether disrupting that candidate selectively impairs leukemia cells. The resulting targets may include enzymes, signaling proteins, regulators of protein synthesis or metabolic components. The study’s significance lies in this systems-level connection: it attempts to move from molecular description to a rational explanation of why a specific leukemia might respond to a specific therapeutic strategy.

This framework could also help explain treatment resistance, one of AML’s most persistent clinical problems. Therapy may eliminate a large fraction of leukemia cells while leaving behind a smaller population with a different metabolic program or a more resilient signaling network. Those surviving cells can expand and drive relapse. If resistant cells are distinguishable by their proteins or metabolites, clinicians may eventually be able to monitor them more directly than by relying on mutation profiles alone. A genomic test might indicate that the cancer has not changed, while proteomic or metabolic measurements could reveal that the cells have shifted into a drug-tolerant state. Such information could support combination treatments designed to attack both the original driver and the adaptive pathway that allows residual disease to persist.

The study also illustrates why precision oncology increasingly depends on combining technologies rather than searching for a single universal biomarker. Each molecular layer has limitations. Genomic data can be comprehensive but mechanistically ambiguous; proteomic data can reflect cellular activity but vary with sample handling and cell composition; metabolomic data can capture rapid physiological changes but may be especially sensitive to environmental conditions. Integration requires careful computational analysis, normalization and biological interpretation. It also demands attention to the fact that a bone-marrow sample contains more than leukemia cells, including immune cells, stromal cells and normal blood precursors. Distinguishing tumor-intrinsic signals from signals produced by the surrounding microenvironment is essential before any proposed subtype or target can be translated into clinical use.

For patients, the immediate impact of this research is likely to be indirect rather than a new treatment available overnight. Molecular subtypes and candidate targets must be validated across independent patient groups, tested in leukemia models and evaluated in clinical trials. Researchers must determine whether a proposed biomarker can be measured reliably in hospitals, whether it predicts response better than existing tests and whether targeting the associated pathway is safe. Even so, the study represents an important shift in how AML can be understood. Instead of treating the disease as a list of mutations, it presents leukemia as an interconnected system in which genetic changes, protein activity and metabolism reinforce one another. That systems view could help researchers identify vulnerabilities that remain hidden when cancer is examined through only one molecular lens.

The broader message is that the future of AML medicine may depend on measuring function as well as identity. A tumor’s DNA records its history, but its proteins and metabolites reveal how that history is being enacted in real time. By bringing these layers together, the researchers offer a route toward more biologically precise disease classification and a more disciplined way to nominate therapeutic targets. The approach will not eliminate AML’s complexity, but it may make that complexity useful: distinct molecular states could become markers for diagnosis, guides for treatment selection and warning signs for relapse. As integrated profiling becomes faster and more accessible, the most important question in leukemia care may shift from “Which mutation does this cancer carry?” to “Which molecular program is sustaining it—and how can that program be interrupted?”

Subject of Research: Integrated molecular profiling of acute myeloid leukemia to identify molecular subtypes and therapy targets.

Article Title: Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.

Article References: Chu, SC.A., Hsiao, Y., Wang, C. et al. Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets. Nature Cancer 7, 993–1015 (2026). https://doi.org/10.1038/s43018-026-01175-6

Image Credits: AI Generated

DOI: 10.1038/s43018-026-01175-6

Keywords: acute myeloid leukemia, AML, proteogenomics, metabolomics, cancer metabolism, molecular subtypes, precision oncology, therapy targets, leukemia biology, cancer biomarkers

Chemotherapy remains a cornerstone in the treatment of many cancers, including AML, a type of blood cancer characterized by rapid proliferation of abnormal white blood cells. The variance in individual responses to treatment can often lead to suboptimal outcomes, making it critical to identify reliable biomarkers for tailoring therapies to each patient’s unique profile. In their research, Wu and colleagues shine a light on two specific proteins—ARTN and CCL23—indicating their roles in the therapeutic response of AML patients.

In essence, ARTN, or artemin, is part of the neurotrophic factor family, influencing neuronal development and function by activating specific receptors. CCL23, on the other hand, is a chemokine that plays a pivotal role in the immune response, attracting monocytes to sites of inflammation. Both proteins had not previously been linked directly to chemotherapy response, making the revelations from this study particularly significant and groundbreaking.

Utilizing Olink® proteomics, the research harnesses a highly sensitive and specific technology designed to measure multiple proteins simultaneously. This method allows for a comprehensive analysis of the proteomic landscape in AML patients, which significantly enhances the ability to detect subtle changes in protein expression that may influence chemosensitivity. The innovative application of this technique marks a critical advancement in understanding the biological underpinnings of AML.

As part of the research, the scientists conducted a thorough investigation that involved analyzing blood samples from AML patients, assessing the levels of ARTN and CCL23 before and after chemotherapy treatments. They discovered that variations in these proteins were closely correlated with the patients’ responses to chemotherapy, thereby reinforcing their potential as biomarkers for predicting treatment efficacy. This correlation is particularly important given the variability in how patients metabolize and respond to chemotherapeutic agents.

Furthermore, the findings suggest that measuring the levels of ARTN and CCL23 could significantly expedite the process of determining the most effective treatment plan for AML patients. This approach not only enhances personalized treatment strategies but also has the potential to reduce the time required to select the right therapeutic regimen, minimizing the risks associated with trial and error methods currently employed in clinical settings.

The implications of such research stretch beyond AML alone, as the integration of proteomic data into clinical practice can pave the way for more effective treatment protocols across various cancers. In an era where precision medicine is becoming increasingly pivotal, such advancements underscore the necessity of leveraging biomarker research to optimize chemotherapy outcomes and overall patient survival.

The study also draws attention to the growing importance of multi-omics approaches in cancer research. By synthesizing data from different biological layers—genomics, proteomics, and transcriptomics—researchers can establish a more intricate understanding of disease pathways, ultimately leading to better-targeted therapies. The introduction of Olink® proteomics into the investigation of AML’s response to chemotherapy exemplifies this innovative trend in medical research.

Moreover, the research team emphasizes the necessity of further studies with larger cohorts to validate these findings and expand the knowledge of these biomarkers. As science progresses, the hope is that ARTN and CCL23 could integrate into routine clinical practice, improving the predictability of chemotherapy responses and tailoring treatments based on each patient’s distinct tumor biology.

The release of these findings contributes to a sense of urgency in the scientific community to accelerate research efforts focused on tumor biomarkers. With many patients facing dire prognoses in the absence of effective therapies, the role of innovative proteomic technologies like those employed in this study cannot be overstated. Just as previous advancements in molecular biology revolutionized our understanding of cancer, the current trajectory promises to yield transformative changes to how we diagnose and treat this complex disease.

This research drives home the message that predictive biomarkers are integral to the future of oncology. As elucidated by the team led by Wu et al., the road ahead is one filled with potential. Embracing novel scientific methodologies will be crucial in delineating which patients will benefit from specific therapies, ultimately enhancing the quality of care and improving survival rates in patients afflicted with acute myeloid leukemia. Every ounce of effort invested in research today lays the groundwork for the sinews of advanced medical practices tomorrow.

In conclusion, the innovative exploration of ARTN and CCL23 as biomarkers for chemosensitivity in acute myeloid leukemia underscores the importance of advanced proteomic technologies in personalizing cancer treatments. This research not only highlights specific proteins that could help predict patient responses but also reinforces the ongoing dialogue regarding the future of tailored therapies in the realm of cancer treatment. The benefits of such work extend beyond laboratory findings, promising a brighter future for patients battling this insidious disease.

Subject of Research: Predicting chemosensitivity in acute myeloid leukemia (AML) using biomarkers.

Article Title: ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink® proteomics approach.

Article References:

Wu, TS., Hsiao, TH., Chen, CH. et al. ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink^® proteomics approach. Clin Proteom 22, 3 (2025). https://doi.org/10.1186/s12014-025-09527-7

Image Credits: AI Generated

DOI:

Keywords: Biomarkers, Acute Myeloid Leukemia, Chemotherapy Response, Olink Proteomics, ARTN, CCL23